Clinical Trial to Treat Stage IV Cancer Patients

Part of paid clinical trials in Hershey, Pennsylvania.

Sponsor
Moonshot Antibodies
Study ID
NCT06674538
Phase
PHASE1
Status
Enrolling By Invitation

Conditions

  • Soft Tissue Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Moonshot antibodies — DRUG
    Chimeric antibodies

Study Details

The purpose of this research is to study the safety and effectiveness of investigational antibodies attacking certain areas on the surface of cancer cells so that the body can kill the cancer cells. The antibodies will be made in a laboratory from cells taken from each subject's tumor so they will be made specifically per subject. The first step is to take blood and tumor samples so that the laboratory can produce antibodies specific to each subject's tumor. During this process, the study team will identify specific areas on the cancer cells that are not normally present in healthy cells so that the antibodies can find the cancer cells that should be destroyed. The second step is to deliver the antibodies to each subject through a series of infusions.

Key Dates

Start date
Dec 30, 2024
Status verified
Sep 2025
Primary completion
Jan 31, 2027
Completion
Jan 31, 2029

Study Design

Enrollment
12 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment group
    Treatment with multiple patient-specific mutated cell surface proteins with chimeric antibodies

Primary Outcome Measure

Safety: Frequency of Grade III or greater adverse events [ Time Frame: From first dose of treatment through endpoint evaluation at 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Penn State Cancer InstituteHersheyPennsylvania17033-

Find similar trials in Hershey, PA

By research site
Penn State Cancer Institute· Hershey, PA

Related Studies